Quanterix Set to Announce Q4 Earnings on March 2nd
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 01 2026
0mins
Should l Buy QTRX?
Source: seekingalpha
- Earnings Announcement Schedule: Quanterix (QTRX) is set to announce its Q4 earnings on March 2nd after market close, with a consensus EPS estimate of -$0.48, reflecting a significant 60% year-over-year decline, indicating potential profitability challenges for the company.
- Revenue Growth Expectations: Despite the weak EPS outlook, Quanterix's revenue estimate stands at $37.95 million, representing a 7.8% year-over-year increase, suggesting that the company maintains some resilience in revenue growth, possibly reflecting stable product demand.
- Historical Performance Review: Over the past year, Quanterix has beaten EPS estimates 50% of the time and has exceeded revenue estimates 100% of the time, which may bolster investor confidence ahead of the upcoming earnings report, although overall profitability remains a concern.
- Executive Changes Impact: With Illumina appointing a former NIH official as its medical chief, Quanterix has also welcomed a new commercial chief, which could bring a fresh strategic direction to the company and further drive revenue growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QTRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QTRX
Wall Street analysts forecast QTRX stock price to rise
2 Analyst Rating
0 Buy
2 Hold
0 Sell
Hold
Current: 3.500
Low
7.00
Averages
7.50
High
8.00
Current: 3.500
Low
7.00
Averages
7.50
High
8.00
About QTRX
Quanterix Corporation is a life sciences company. The Company is focused on ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development proprietary digital Simoa detection technology enables customers to reliably detect protein biomarkers at ultra-low concentrations in blood, serum and other fluids that, in many cases, are undetectable using conventional, analog immunoassay technologies. Its Simoa bead-based digital immunoassays utilize the basic principles of conventional bead-based sandwich ELISA. The HD-X is the Company's flagship instrument that empowers biomarker research and accelerates drug development. Its SR-X instrument is a compact benchtop instrument with a lower price point, more flexible assay preparation, and a wider range of applications. The Company's Spatial Biology solutions measure protein expression and cellular phenotypes within intact tissue while preserving spatial context and tissue architecture.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AidaBREAST™ First to Predict Recurrence Risk in Early-Stage Breast Cancer
- Innovative Diagnostic Tool: AidaBREAST™ is the first multi-omic assay capable of predicting both locoregional recurrence risk and radiation therapy benefit for early-stage invasive breast cancer patients, marking a significant milestone in the clinical translation of spatial proteomics.
- Clinical Validation Data: The assay was validated in a cohort of 922 hormone receptor-positive, HER2-negative breast cancer patients across four academic and clinical centers in the U.S. and Sweden, with a median follow-up of approximately 10 years, demonstrating its effectiveness in predicting 10-year locoregional recurrence risk and radiation therapy benefit.
- Technological Advantage: AidaBREAST leverages the PhenoImager HT platform and Opal chemistry, integrating targeted next-generation RNA sequencing for a comprehensive assessment of tumor biology, enabling physicians to make more personalized treatment decisions.
- Industry Impact: The collaboration between PreludeDx and Quanterix showcases the potential of spatial proteomics in clinical oncology, with the launch of AidaBREAST poised to advance personalized medicine and assist patients and physicians in making more informed treatment choices.
See More
Quanterix Unveils Content Innovation Engine to Advance Cancer Biology Research
- Content Innovation Engine Launch: Quanterix announced the debut of its Content Innovation Engine at the 2026 AACR Annual Meeting, integrating Akoya's spatial biology platform with Quanterix's ultra-sensitive immunoassay technology to systematically unlock cancer biology and accelerate clinical applications.
- Edison Award Nomination: The PhenoCode™ Discovery IO60 panel has been named a finalist for the Edison Awards, showcasing its deep coverage in immunotherapy biology, particularly in key therapeutic markers such as PD-1/PD-L1 and CTLA-4.
- New Product Introduction: Quanterix will introduce the PhenoCode Molecular Barcoding Kit at AACR, enabling researchers to barcode virtually any antibody with exceptional reliability and yield, with early access expected to begin in May 2026.
- ADC Lung Cancer Panels: Quanterix will present two new ADC lung cancer panels at AACR, building on the success of its ADC breast cancer panel, now available as a fully managed service, further advancing cancer research efforts.
See More
Quanterix (QTRX) Q4 2025 Earnings Call Transcript
See More
Quanterix Corporation Q4 2025 Earnings Call Insights
- Leadership Transition: New CEO Everett Cunningham emphasizes his extensive background in healthcare and commercial strategy, aiming to accelerate Quanterix's growth particularly in neurology, oncology, and immunology, reflecting the company's focus on market opportunities.
- Financial Performance: Q4 total revenue reached $43.9 million, a 25% year-over-year increase, although organic revenue declined by 22%, with $3.1 million generated from diagnostics partners, indicating strong performance in the research tools segment and potential from new product launches.
- Cost Synergy Targets: CFO Vandana Sriram reported that $74 million of the $85 million cost synergy target has been achieved, with expectations to meet the target by the end of Q1, showcasing the company's proactive approach to cost control and efficiency improvements.
- 2026 Outlook: The company anticipates revenue between $169 million and $174 million for 2026, despite ongoing weakness in academic and pharmaceutical markets, with management expressing confidence in achieving cash flow breakeven and continued investment in high-impact diagnostic tools.
See More
Quanterix Q4 Earnings Beat Expectations Despite EPS Miss
- Earnings Highlights: Quanterix reported a Q4 GAAP EPS of -$0.49, missing expectations by $0.01, yet achieved revenue of $43.9M, reflecting a 24.7% year-over-year growth and surpassing estimates by $5.95M, indicating strong market demand.
- Executive Changes Impact: Illumina's appointment of a former NIH official as medical chief and a commercial chief joining Quanterix is expected to enhance the company's strategic direction and innovation capabilities, potentially driving future growth.
- Positive Market Reaction: Quanterix gained attention from investors due to the CEO change and optimistic revenue guidance, suggesting a bullish outlook that could positively influence stock performance in the near term.
- Analyst Ratings: Seeking Alpha's Quant Rating on Quanterix reflects market confidence in its growth prospects, indicating that despite the short-term EPS miss, the long-term outlook remains favorable.
See More
Lucent Diagnostics Partners with Life Line Screening for National Testing
- Partnership Announcement: Lucent Diagnostics has partnered with Life Line Screening (LLS) to offer its non-invasive blood-based biomarker test nationally, with programs already underway in Florida, California, and Texas, aiming to enhance public awareness and early detection of chronic conditions.
- Public Health Urgency: The Alzheimer's Association reports that approximately 7 million Americans are currently living with Alzheimer's disease, with an additional 6-7 million experiencing Mild Cognitive Impairment (MCI), highlighting the urgent need for scalable testing options to facilitate early identification during the most treatable phases of the disease.
- Community Testing Network: LLS will leverage its mobile delivery model to provide testing opportunities in local venues such as community centers, churches, and senior centers, ensuring that test results can assist primary care physicians in early intervention and proactive lifestyle management, thereby impacting numerous lives.
- Scientific Rigor: By integrating validated, high-quality science into community testing networks through LLS, Lucent Diagnostics ensures that everyone has access to critical information for their physicians, marking a significant step toward earlier and more reliable detection of Alzheimer's disease.
See More
AidaBREAST™ First to Predict Recurrence Risk in Early-Stage Breast Cancer
- Innovative Diagnostic Tool: AidaBREAST™ is the first multi-omic assay capable of predicting both locoregional recurrence risk and radiation therapy benefit for early-stage invasive breast cancer patients, marking a significant milestone in the clinical translation of spatial proteomics.
- Clinical Validation Data: The assay was validated in a cohort of 922 hormone receptor-positive, HER2-negative breast cancer patients across four academic and clinical centers in the U.S. and Sweden, with a median follow-up of approximately 10 years, demonstrating its effectiveness in predicting 10-year locoregional recurrence risk and radiation therapy benefit.
- Technological Advantage: AidaBREAST leverages the PhenoImager HT platform and Opal chemistry, integrating targeted next-generation RNA sequencing for a comprehensive assessment of tumor biology, enabling physicians to make more personalized treatment decisions.
- Industry Impact: The collaboration between PreludeDx and Quanterix showcases the potential of spatial proteomics in clinical oncology, with the launch of AidaBREAST poised to advance personalized medicine and assist patients and physicians in making more informed treatment choices.
See More
Quanterix Unveils Content Innovation Engine to Advance Cancer Biology Research
- Content Innovation Engine Launch: Quanterix announced the debut of its Content Innovation Engine at the 2026 AACR Annual Meeting, integrating Akoya's spatial biology platform with Quanterix's ultra-sensitive immunoassay technology to systematically unlock cancer biology and accelerate clinical applications.
- Edison Award Nomination: The PhenoCode™ Discovery IO60 panel has been named a finalist for the Edison Awards, showcasing its deep coverage in immunotherapy biology, particularly in key therapeutic markers such as PD-1/PD-L1 and CTLA-4.
- New Product Introduction: Quanterix will introduce the PhenoCode Molecular Barcoding Kit at AACR, enabling researchers to barcode virtually any antibody with exceptional reliability and yield, with early access expected to begin in May 2026.
- ADC Lung Cancer Panels: Quanterix will present two new ADC lung cancer panels at AACR, building on the success of its ADC breast cancer panel, now available as a fully managed service, further advancing cancer research efforts.
See More
Quanterix (QTRX) Q4 2025 Earnings Call Transcript
See More
Quanterix Corporation Q4 2025 Earnings Call Insights
- Leadership Transition: New CEO Everett Cunningham emphasizes his extensive background in healthcare and commercial strategy, aiming to accelerate Quanterix's growth particularly in neurology, oncology, and immunology, reflecting the company's focus on market opportunities.
- Financial Performance: Q4 total revenue reached $43.9 million, a 25% year-over-year increase, although organic revenue declined by 22%, with $3.1 million generated from diagnostics partners, indicating strong performance in the research tools segment and potential from new product launches.
- Cost Synergy Targets: CFO Vandana Sriram reported that $74 million of the $85 million cost synergy target has been achieved, with expectations to meet the target by the end of Q1, showcasing the company's proactive approach to cost control and efficiency improvements.
- 2026 Outlook: The company anticipates revenue between $169 million and $174 million for 2026, despite ongoing weakness in academic and pharmaceutical markets, with management expressing confidence in achieving cash flow breakeven and continued investment in high-impact diagnostic tools.
See More
Quanterix Q4 Earnings Beat Expectations Despite EPS Miss
- Earnings Highlights: Quanterix reported a Q4 GAAP EPS of -$0.49, missing expectations by $0.01, yet achieved revenue of $43.9M, reflecting a 24.7% year-over-year growth and surpassing estimates by $5.95M, indicating strong market demand.
- Executive Changes Impact: Illumina's appointment of a former NIH official as medical chief and a commercial chief joining Quanterix is expected to enhance the company's strategic direction and innovation capabilities, potentially driving future growth.
- Positive Market Reaction: Quanterix gained attention from investors due to the CEO change and optimistic revenue guidance, suggesting a bullish outlook that could positively influence stock performance in the near term.
- Analyst Ratings: Seeking Alpha's Quant Rating on Quanterix reflects market confidence in its growth prospects, indicating that despite the short-term EPS miss, the long-term outlook remains favorable.
See More
Lucent Diagnostics Partners with Life Line Screening for National Testing
- Partnership Announcement: Lucent Diagnostics has partnered with Life Line Screening (LLS) to offer its non-invasive blood-based biomarker test nationally, with programs already underway in Florida, California, and Texas, aiming to enhance public awareness and early detection of chronic conditions.
- Public Health Urgency: The Alzheimer's Association reports that approximately 7 million Americans are currently living with Alzheimer's disease, with an additional 6-7 million experiencing Mild Cognitive Impairment (MCI), highlighting the urgent need for scalable testing options to facilitate early identification during the most treatable phases of the disease.
- Community Testing Network: LLS will leverage its mobile delivery model to provide testing opportunities in local venues such as community centers, churches, and senior centers, ensuring that test results can assist primary care physicians in early intervention and proactive lifestyle management, thereby impacting numerous lives.
- Scientific Rigor: By integrating validated, high-quality science into community testing networks through LLS, Lucent Diagnostics ensures that everyone has access to critical information for their physicians, marking a significant step toward earlier and more reliable detection of Alzheimer's disease.
See More
